KRAS and non-small cell lung carcinoma: Expectedly, known oncogenic activating alterations in KRAS, BRAF, ALK, and ROS1 were mutually exclusive with EGFR alterations, similar to the observation in KRAS-altered non-Sq NSCLC (Fig. 3c, Supplementary Data 11).